Griffithsin, which binds N-linked glycans on gp120 to prevent HIV entry, has the most potent 19
in vitro and in a murine model. Safety was evaluated by examining its impact on epithelial 23 barrier integrity in polarized cultures and testing whether repeated intravaginal dosing 24 potentiates the susceptibility of mice to genital herpes. Griffithsin displayed modest inhibitory 25 activity against HSV-2 if present during viral entry, but completely blocked plaque formation if 26 present post-entry, reduced plaque size, and prevented cell-to-cell spread. These in vitro 27 findings translated to significant protection against genital herpes in mice treated with 0.1% 28 griffithsin gel. Griffithsin, but not placebo gel, prevented viral spread (visualized with a 29 luciferase-expressing virus), significantly reduced disease scores and resulted in greater 30 survival (p< 0.05, log rank test). Protection persisted when HSV-2 was introduced in seminal 31 plasma. Although griffithsin triggered a small decline in transepithelial electrical resistance in 32 polarized cultures, this did not translate to any significant increase in the ability of HIV to migrate 33 from the apical to the basolateral chamber nor to an increase in susceptibility to HSV-2 in mice 34 treated with griffithsin gel for seven days. These findings demonstrate that griffithsin inhibits 35 HSV-2 by a unique mechanism of blocking cell-to-cell spread and support its further 36 development for HIV and HSV-2 prevention. There has been exciting progress in the development of oral and topical products for the 40 prevention of HIV and HSV-2. The recent CAPRISA 004 trial, in which a 39% (95%CI 6-61%) 41 reduction in HIV and a 54% reduction in HSV-2 acquisition were observed in women who 42 applied 1% tenofovir gel before and after sex, illustrated the potential for delivering safe and 43 effective vaginal prevention products (3). However, the finding that tenofovir vaginal gel applied 44 daily provided no protection against HIV acquisition in the recently discontinued arm of the 45
Microbicide Trials Network 003 (VOICE) trial highlights the complexities of delivering pre-46 exposure prophylactic (PrEP) strategies (2). Similarly, there have been conflicting results with 47 oral PrEP clinical trials. For example, efficacies of 66% and 73% were observed among women 48 taking daily oral tenofovir disoproxil fumarate (TDF) (Viread) or the combination of TDF and FTC 49 (Truvada), respectively, in the Partners in Prevention trial, whereas the VOICE oral TDF arm 50 and the FEMPReP Truvada study were discontinued early for futility (1, 5, 9, 52). The 51 differences in outcomes likely reflect a combination of behavioral and biomedical factors 52 including adherence to product, differences in the populations studied (e.g. discordant couples 53 in Partners), and mucosal inflammation. Inflammation, which may be triggered in response to 54 hormonal contraception, other sexually transmitted infections, and changes in vaginal 55 microbiota, may promote HIV acquisition and modulate drug efficacy and pharmacokinetics 56
(29). 57
The discrepant clinical trial outcomes highlight the need to develop additional products 58 that could be used either alone or in combination with tenofovir to improve the efficacy of 59 prevention strategies. One such candidate is Griffithsin (GRFT). GRFT is a small homodimeric 60 lectin that was isolated from a red alga (Griffithsia sp.) and binds to clusters of oligomannose N-61 linked glycans on the HIV-1 envelope glycoprotein gp120 to prevent viral entry. GRFT has the 62 most potent and broad spectrum HIV-1 inhibitory activity yet described for any antiviral lectin 63 and showed synergistic activity with tenofovir in vitro (4, 15, 16, 39). Importantly, it is unlikely 64 on June 28, 2017 by guest http://jvi.asm.org/ Downloaded from percentage of plaques relative to plaques formed on control wells (no drug) were calculated. 143
Immature moDCs (1x10 6 cells) were pretreated with GRFT (10, 100 or 500µg/ml) overnight at 144 37°C and were then challenged with HSV-2(333)ZAG (moi 1PFU/cell) or mock-infected by being 145 exposed to RPMI with 10% FBS. After incubation for 1 h at 37°C, the cells were washed three 146 times with PBS, and were then cultured in fresh medium for 4h. GFP expression, as a marker of 147 viral infection, was quantified by flow cytometry after gating on the live populations using a 148 fixable violet Live/Dead marker (Invitrogen, Carlsbad, CA). Ten thousand live events were 149 acquired per sample. To determine if GRFT blocked release of infectious progeny from DCs, the 150
DCs were infected with HSV-2 for 1 h in the absence or presence of GRFT, and then after 151 washing as above, the cells were cultured for 24 h in medium containing GRFT or medium 152 alone and viral release quantified by titering the culture supernatants on Vero cells. 153
Single-step and multistep growth of virus:
To measure single-step growth of virus, CaSki 154 cells were infected with HSV-2(4674) (MOI 5 pfu/cell) for 1 h at 37°C. Cells were washed for 2 155 min with a low pH citrate buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl, pH 3.0] for 2 min 156 to inactivate extracellular virus and then washed three times with media prior to overlaying the 157 cells with 199V alone or supplemented with GRFT (100µg/ml) or ACV (100µg/ml). Supernatants 158 and cells were harvested separately 4h, 8h and 16h pi and stored at -80°C until plating on Vero 159 cells to measure infectious virus. Cells were frozen and thawed three times to cause lysis prior 160 to infecting Vero cells. For multistep growth assays, the CaSki cells were infected with HSV-161 2(4674) (MOI 0.01 pfu/cell) for 1 h at 37°C as above and supernatants and cells were harvested 162 at 12h, 24h, 36h, 48h, and 72h pi and titered on Vero cells as described for single step growth 163
experiments. 164
Measurement of viral DNA levels using real-time quantitative PCR (RT-qPCR): CaSki cells 165 were infected with virus at an MOI of 1 for 1 h at 37°C. Cells were washed with citrate buffer 166 once and with medium three times and then cultured in 199V alone or supplemented with 100 167 µg/ml GRFT or ACV. At 8h and 12h pi, cells were harvested and DNA was extracted using Cells were apically exposed to GRFT (100 and 1000 µg/ml) or 0.1% N-9 for 16 h. Drug was 180 removed by washing thrice with serum-free medium before addition of HIV-1 BaL (40 ng of p24 181 antigen) in medium and JT-CCR5 cells to the AP and BL chambers, respectively. Cultures were 182 maintained for an additional 5 days and BL supernatants were collected at different times and 183 tested for p24 content as previously described (33). 184 Drug toxicity and cell apoptosis analysis: Cells (CaSki, VK2/E6E7, 3T3 and immature 185 moDCs were exposed to 10, 100 or 500µg/ml of GRFT or medium as a negative control 186 overnight (moDCs) or for 48 h (CaSki, VK2/E6E7 and 3T3) at 37°C and cell viability was 187 assessed using a MTS assay (Promega, Madison, WI). In addition, the DCs were harvested and 188 analyzed for early and late signs of apoptosis using an annexin V and 7AAD staining protocol 189 (BD Pharmingen, San Diego, CA). Cells were analyzed by flow cytometry, acquiring ten 190 thousand events per sample (50). To assess whether GRFT had an impact on DC maturation or 191 function, DCs were treated with GRFT (10, 100 or 500µg/ml), lipopolysaccharide (LPS) 192 were counted after 24-48 h. GRFT had only modest effects on HSV plaque formation and 255 reduced the number of plaques by less than 50% even at the highest concentration (500 µg/mL) 256 when drug was present during viral entry, while PRO 2000 completely blocked plaque formation 257 (Fig. 1A) . Similarly, GRFT failed to block infection of immature moDCs when cells were 258 pretreated with the drug; infection was monitored by quantifying GFP expression 4 h post-259 exposure to HSV-2(333)(GFP) (Fig. 1B) . However, when GRFT was added post-entry to CaSki with the absence of any effects on the single-step growth curve, GRFT had little or no effect on 273 HSV DNA levels measured by RT-qPCR of ICP4 DNA 8 or 12 h post-infection, whereas ACV 274 significantly reduced viral DNA levels (Fig. 2C) . Moreover, GRFT had no impact on the release 275 of infectious progeny from moDCs when drug was added pre or post-entry as monitored by 276 titering the DC culture supernatants on Vero cells 24 h pi (Fig. 1B) . Taken together, these 277 findings indicate that GRFT likely interferes with cell-to-cell spread of HSV-2. 278
To further address this, infectious center assays were conducted (11). Uninfected cells 279
were co-cultured with ~500 infected cells in the presence of pooled human immunoglobulin. The 280 pooled immunoglobulin neutralizes any released virus restricting viral spread to local fusion 281 events between the plasma membranes of infected and uninfected cells. The addition of GRFT 282 to the co-cultures completely blocked cell-to-cell spread in CaSki and VK2/E6E7 cells at 100 283 and 500μg/ml, respectively (Fig. 2D) . 284
GRFT inhibits viral infection in the murine model. The observation that GRFT prevents cell-285 to-cell spread suggests that it could be an effective agent against viral dissemination and 286 mitigate genital herpes disease. To evaluate this, medroxyprogesterone-treated mice received a 287 single application of GRFT (0.1% gel), placebo carbopol gel or no gel 15 min prior to challenge 288 with an LD50 or LD90 of HSV-2 (based on prior studies with placebo gels). Virus was delivered 289 in PBS or pooled human seminal plasma to simulate what may happen clinically. Mice were 290 monitored and scored for 14 days for signs of disease. GRFT protected the mice from HSV-2 291 disease compared to carbopol-treated and untreated (no gel) animals, regardless of whether 292 virus was introduced in PBS or seminal plasma (Fig. 3A-C, p< 0.05) . Notably, at the higher 293 inoculum (LD90), greater protection was observed when mice were challenged with HSV-2 in 294 seminal plasma compared to when virus was introduced in PBS (Fig. 3B) . 295
The in vivo protective effects of GRFT were further evaluated by harvesting genital tract 296 tissue and assaying for infectious virus. HSV-2 was recovered from excised homogenized 297 on June 28, 2017 by guest http://jvi.asm.org/ Downloaded from genital tract tissue in 9/10 mice that received carbopol (median log titer 3.92 PFU/gm tissue) 298 and 6/10 mice who received GRFT (median log titer 3.46 PFU/gm tissue) one day pi (p=0.11). 299
Virus was recovered from 3/5 mice that received carbopol gel (median log titer 1.10 PFU/gm 300 tissue) compared to 0/5 mice that received GRFT 7 days pi (p=0.07, unpaired t-test) 7 days pi 301 (Fig. 3D) . 302
To further examine the impact of GRFT on genital herpes, we took advantage of an 303 HSV-2 variant, MS-Luciferase, in which a luciferase expression cassette was inserted into the 304 LAT locus (21) and monitored viral spread using bioluminescent imaging. Mice were pretreated 305 with carbopol or GRFT gel and then challenged with 10 6 pfu of MS-Luciferase. In the carbopol-306 treated mice, luciferase activity increased by an average of 2.7-fold and 4.7-fold compared to 307 background (uninfected mouse treated with D-luciferin) on Days 1 and 4 post-viral challenge, 308 respectively (Fig. 4) . GRFT treated mice showed no increase in luciferase activity compared to Consistent with prior studies (19, 55), there was an increase in vaginal wash levels of IFN-γ and 320 several pro-inflammatory mediators including IL-6, IL-1β, MIP-1β, and MIP-2 in HSV-2 infected 321 compared to uninfected mice, independent of gel exposure one and/or two days pi (Fig. 5A) . In 322 on June 28, 2017 by guest http://jvi.asm.org/ the absence of virus, GRFT was associated with an increase in IL-1β, MIP-1β and MIP-2 on 323
Day 1 compared to untreated mice and Carbopol was associated with higher levels of IL-6 on 324
Day 1 and MIP-1 on Day 2 compared to GRFT-treated mice (p<0.05). The biological 325 significance of these modest changes requires further study. 326
To further explore the impact of GRFT on the IFN response to virus, RNA was isolated 327 from genital tract tissue and analyzed by RT-qPCR on days 1 and 3 pi. HSV-2 induced 328 upregulation of several IFN genes including IFN-γ, Oas2, IRF-7 and Mx1 with a small reduction 329 in these responses in mice pretreated with GRFT (Fig. 5B) . GRFT itself had no impact on IFN 330 responses compared to untreated mice. These findings are consistent with the in vitro 331
observations that GRFT has only modest effects on HSV entry (Fig. 1) and that viral entry may 332 be sufficient to induce an initial IFN response (12, 43). 333
Evaluation of the safety of 0.1% GRFT gel: There was no reduction in CaSki, VK2/E6E7, 3T3 334 or moDC viability in response to 48 h exposure to GRFT in vitro (Fig 6A) . To further explore 335 safety, we took advantage of two additional preclinical safety models that focus on the impact of 336 drugs on mucosal integrity. HEC-1-A cells were cultured on Transwell inserts until the 337 transepithelial electrical resistance (TER) reached a steady state of ~300 Ω.cm 2 (typically Day 338 4-5 after plating cells). The polarized cells were exposed apically to a single dose of GRFT (0.1 339 and 1mg/ml), N-9 (0.1% (v/v)) or culture medium (negative control) for 18 h and then washed 340 three times. HIV-1 BaL was added to the AP chamber and JT-CCR5 cells to the BL chamber. The 341 TER and p24 content in BL culture supernatants were measured daily ( Fig. 6B and 6C ). The 342 former provides a measure of barrier integrity and the latter of HIV transmigration across the 343 epithelium. Additional controls included inserts in which no cells were seeded, a measure of the 344 maximal migration of HIV across the insert pores (positive control) and wells in which no HIV 345 was added (p24 background). After application of N-9, the TER fell rapidly and HIV freely 346 traversed the disrupted epithelium resulting in p24 levels comparable to those observed in the 347 on June 28, 2017 by guest http://jvi.asm.org/ Downloaded from absence of any cells (positive control). Exposure to both concentrations of GRFT resulted in a 348 modest and less sustained decline in TER, which differed significantly from medium alone. This 349 was associated with a modest increase in HIV p24 levels in the BL compartment that did not 350 reach statistical significance compared to medium alone; only a small amount of HIV traverses 351 the barrier when cells are cultured in medium (Fig. 6B) . 352
GRFT does not increase susceptibility to HSV-2 in a mouse safety model. To determine if 353
the modest decline in TER and concomitant increase in HIV p24 levels in the dual chamber 354 model translated to increased susceptibility to HSV-2 in mice, mice were treated once daily for 7 355 consecutive days with 0.1% GRFT gel, carbopol gel, or 4% N-9 gel and then 12-24 hours after 356 the last dose, vaginal washes were collected to remove any residual luminal drug and 357 subsequently assayed for anti-HIV activity. There was sufficient GRFT within the vaginal 358 washes to inhibit HIV-1 infection in a TZM-bl assay; N-9 washes had no antiviral activity (Fig  359   7A) . The mice were then challenged with an LD10, LD50 and LD90 of virus. Consistent with 360 prior studies, there was an increase in mortality in N-9 treated compared to carbopol treated 361 mice following challenge with the LD10 or LD50 dose of virus (p<0.05) (Fig. 7B and 7C) . In 362 contrast, survival rates between GRFT and carbopol treated mice did not differ significantly at 363 any of the challenge doses. All of the mice succumbed to infection following exposure to an 364 LD90 (Fig. 7D) , indicating that when GRFT drug is removed, protection against HSV-2 is lost. 365
Exposure to GRFT has no deleterious impact on human DCs. Lectins such as GRFT may 366
modulate DC function by interacting with carbohydrates on DC surface. To assess whether 367 GRFT induced DC maturation or interfered with the maturation response to LPS, cells were 368 exposed to medium or GRFT drug for 24 h and were then stained and analyzed for the 369 expression of CD83, a cell surface marker of DC maturation. There was no increase in CD83 370 expression in response to GRFT compared to mock (medium) treated cells. However, LPS 371 (Fig. 8A) . In addition, GRFT did not induce apoptosis in DCs compared to the mock-374 exposed cells (Fig. 8B) . Together these findings indicate that GRFT does not adversely impact 375 DC function. 376
DISCUSSION 377
The current studies were initially designed to further evaluate the safety of GRFT, which 378 is being advanced as a candidate vaginal product to prevent HIV infection. An unexpected 379 finding was that GRFT inhibited HSV-2 infection post-entry by blocking cell-to-cell spread (Figs. 380 1 and 2) and protected mice from genital herpes disease (Fig. 3) . There was little dissemination 381 of virus in mice treated with a single dose of gel prior to vaginal inoculation as evidenced by the 382 imaging studies with a luciferase-reporter virus (Fig. 4) . Importantly, GRFT retained its 383 protective activity in the mice when virus was introduced in human seminal plasma. The other key findings from this study add to the growing safety profile of GRFT. First, 423 mice responded to HSV-2 exposure with a potent IFN response that was similar in both the 424 on June 28, 2017 by guest http://jvi.asm.org/ Downloaded from carbopol and GRFT treated mice (Fig. 5) . Thus GRFT does not appear to prevent protective 425 mucosal responses. Second, although GRFT induced a modest decrease in the TER and a 426 concomitant statistically not significant increase in HIV migration across the epithelial barrier to 427 infect T cells cultured in the lower chamber (Fig. 6) , this did not translate to increased 428 susceptibility to HSV-2 when mice were treated for 7 days with GRFT and then challenged with 429 sublethal doses of HSV-2. This contrasts with results obtained here and in previous studies with 430 N-9, which triggered a rapid and profound drop in TER and increased the susceptibility of the 431 mice to HSV-2 following intravaginal challenge with either an LD10 or LD50 (Fig. 7) (19, 55) . 432
The results also differ from our studies with cellulose sulfate, which triggered a more sustained 433 decrease in TER and promoted HSV-2 infection in the murine model (33, 46). Third, GRFT was 434 not cytotoxic and had no deleterious effects on DCs. The drug did not induce DC apoptosis or 435 maturation nor did it prevent DCs from responding appropriately to a maturation signal (LPS). 436
Maintenance of DC function is critical as these cells play a sentinel role in mucosal defense and 437 link innate and adaptive immune responses. 438
The protective effects of GRFT against HSV disease, a major co-factor in the HIV 439 epidemic, suggest that GRFT may contribute both directly and indirectly to HIV protection. 
